COVID-19 Vaccine Study COV001

What is the purpose of this trial?

The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.

A new virus causing respiratory disease emerged in Wuhan, China in December 2019 and has since rapidly spread to many other countries around the world, despite unprecedented containment efforts. The virus is part of the Coronavirus family which may cause respiratory infections ranging from the common cold to more severe diseases. This recently discovered coronavirus causes coronavirus disease COVID-19.

What’s the STORY?

The Oxford Vaccine Group is researching a new way of surveying how well protected we are from vaccine preventable diseases by collecting blood samples from people who represent different groups across society.

Understanding RSV: Severe disease and the long term consequences

Understanding RSV: Severe disease and the long term consequences

Oxford Vaccine Group are inviting volunteers to take part in a study to help us learn more about the virus that most commonly causes coughs, colds and chest infections in young children, and sometimes causes children to be so unwell they have to be admitted to hospital.

Some facts about RSV disease (respiratory syncytial virus):

POInT

The Oxford Vaccine Group is recruiting infants aged 4 – 7 months to a type 1 diabetes prevention trial. POInT (Primary Oral Insulin Trial) is recruiting infants who were screened for diabetes at birth through the INGR1D Study and have been found to be at high risk for developing diabetes.

Be on the TEAM: Teenagers against Meningitis

The Oxford Vaccine Group are inviting students in school year 12 to take part in a research project to understand whether immunising teenagers with vaccines against ‘Meningitis B’ could protect them and the rest of the community against these potentially deadly bacteria. This is a national study involving 24 000 year 12 students across the United Kingdom.  Teenagers at participating schools are being asked to take part by local research teams involved.

Burden of RSV Disease

Some facts about RSV disease (respiratory syncytial virus):

RSV is a virus;

  • it causes coughs, colds and chest infections
  • is responsible for around 1 in 6 hospital admissions for infants  in the UK
  • The second largest worldwide cause of deaths in children between one month and 1 year of age, most are in Asia and Africa

What do we want to do?

We would like to identify 2000 babies from birth and follow them up to see if any become unwell with RSV disease

ImmunoglobuliN in the Treatment of Encephalitis

The IgNiTE Study

A study testing a new treatment for children with encephalitis.

The Department of Paediatrics at the University of Oxford, in collaboration with NHS Trusts across the United Kingdom, is currently running a study for hospitalised children with encephalitis. The study will assess whether a treatment called intravenous immunoglobulin (IVIg, sometimes referred to as antibody treatment) has any benefit for these children when given early during the hospital admission.

Subscribe to Trials - Oxford Vaccine Group RSS